Research programme: influenza vaccines - GlaxoSmithKline/KM Biologics
Alternative Names: Influenza virus H5N1 vaccine - GlaxoSmithKline/KM BiologicsLatest Information Update: 06 Nov 2018
Price :
$50 *
At a glance
- Originator GlaxoSmithKline Biologicals; Kaketsuken
- Class Influenza A virus H5N1 vaccines; Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza A virus H5N1 subtype; Influenza virus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-A-virus-H5N1-subtype in Japan
- 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-virus-infections in Belgium
- 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-virus-infections in Japan